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OBJECTIVE—Diabetic retinopathy is associated with progres-
sive retinal capillary activation and proliferation, leading to
vision impairment and blindness. Microparticles are submicron
membrane vesicles with biological activities, released following
cell activation or apoptosis. We tested the hypothesis that
proangiogenic microparticles accumulate in vitreous ﬂuid in
diabetic retinopathy.
RESEARCH DESIGN AND METHODS—Levels and cellular
origin of vitreous and plasma microparticles from control (n 
26) and diabetic (n  104) patients were analyzed by ﬂow
cytometry, and their proangiogenic activity was assessed by in
vitro thymidine incorporation and neovessel formation in subcu-
taneous Matrigel plugs in mice.
RESULTS—Microparticles of endothelial, platelet, photorecep-
tor, and microglial origin were identiﬁed in vitreous samples.
Levels of photoreceptor and microglial microparticles were
undetectable in plasmas but were comparable in diabetic and
control vitreous samples. Vitreous platelet and endothelial mi-
croparticles levels were increased in diabetic patients and
decreased following panretinal laser photocoagulation or
intravitreal antivascular endothelial growth factor injection in
proliferative diabetic retinopathy (PDR). The ratio of vitreous to
plasma microparticle levels was calculated to estimate local
formation versus potential plasma leakage. In PDR, the endothe-
lial microparticles ratio—but not that for platelet—was greater
than 1.0, indicating local formation of endothelial microparticles
from retinal vessels and permeation of platelet microparticles
from plasma. Isolated vitreous microparticles stimulated by
1.6-fold endothelial proliferation and increased new vessel for-
mation in mice.
CONCLUSIONS—The present study demonstrates that vitreous
ﬂuid contains shed membrane microparticles of endothelial,
platelet, and retinal origin. Vitreous microparticles levels are
increased in patients with diabetic retinopathy, where they could
contribute to disease progression. Diabetes 59:694–701, 2010
D
espite advances in medical care, diabetic reti-
nopathy continues to be a leading cause of
vision impairment and blindness in working-age
adults (1). The pathogenesis of diabetic retinop-
athy is complex and has involved multiple pathways
including accumulation of polyol compounds and ad-
vanced glycation end products, increased oxidation stress
and activation of the protein kinase C pathway, production
of growth factors, and inﬂammation (1). Although there is
growing evidence for an early involvement of the neural
elements of the retina (2), vision loss in diabetic retinop-
athy is associated with progressive alterations of the
retinal vasculature, leading to the breakdown of the blood
retinal barrier and pathological angiogenesis of new ves-
sels in the vitreous cavity (1,3). The risk of vision loss
results then from macular edema and bleeding of these
new vessels (vitreous hemorrhage) or their contraction
(retinal detachment).
Microparticles are submicron membrane vesicles shed
from the cell surface of both healthy and damaged cells
(4). Shedding of membrane microparticles is a physiolog-
ical process that accompanies cell growth and activation
and that is enhanced by cytokines, reactive oxygen spe-
cies, activation of apoptotic pathways, or increases in
intracellular calcium leading to cytoskeleton reorganiza-
tion. Numerous studies now indicate that microparticles
have biological activities and may be involved in throm-
bosis, cell inﬂammation, angiogenesis and cell-to-cell com-
munication (5–12).
Microparticles have been identiﬁed not only in human
plasma but also in other tissues with high cellular activa-
tion, inﬂammation, or apoptosis, such as human athero-
sclerotic plaques or synovial ﬂuid in rheumatoid arthritis
(13,14). Plasma microparticles from different cellular ori-
gins circulate in healthy subjects, and their levels increase
in patients with cardiovascular disease (15,16). The ques-
tion of changes in circulating levels of microparticles
appears to be controversial in diabetic patients (17,18), but
plasma levels of platelet-derived and monocyte-derived
microparticles increase with the severity of diabetic reti-
nopathy (19,20).
Diabetic retinopathy is associated with increased local
activation or apoptosis of retinal, neural, and vascular
endothelial cells in the eye both in humans and in animal
models (21–24). These ﬁnding indicate that microparticles
of different cellular origin might be locally generated in the
eye of diabetic patients. Alternatively, the presence of
microparticles in the eye could also result from an in-
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retinopathy. Thus, we sought to investigate the presence
of endothelial, platelet, and retinal-derived microparticles
both in the vitreous and in the plasma of diabetic patients
undergoing vitrectomy for diabetic retinopathy compared
with that of nondiabetic patients. We also examined the
potential biological effects of vitreous microparticles on
endothelial proliferation and new vessel formation.
RESEARCH DESIGN AND METHODS
We included 130 patients who underwent vitrectomy at Lariboisiere Hospital.
Baseline characteristics of diabetic and control patients are given in Table 1.
Patients were eligible for inclusion when they had no vitreous surgery on the
same eye previously and agreed to participate in this study, which was
approved by our Institutional Ethics Committee Board and adhered to the
Declaration of Helsinki. All patients signed a written informed consent. Prior
to surgery, diabetic retinopathy was evaluated according to the simpliﬁed
international diabetic retinopathy classiﬁcation (21), made on the basis of
clinical data, intraoperative assessment by the surgeon, and review of fundus
photographs.
Undiluted vitreous ﬂuid samples (300–400 l) were collected from
patients’ eyes at the start of a standard three-port pars plana vitrectomy for
the treatment of retinal diseases. A central vitrectomy was performed after a
20- or 23-inch gauge sclerotomy at 4 mm from the limbus using a vitreotome
(Accurus). Vitreous samples were collected at the beginning of vitrectomy
before opening the balanced salt solution infusion line to maintain intraocular
pressure and homogenized by gently pipetting the suspension up and down
several times. Ninety-eight samples were collected from the eyes of 93
patients with proliferative diabetic retinopathy (PDR); in these cases, vitrec-
tomy was performed for persistent vitreous hemorrhage, tractional retinal
detachment, or macular edema. Among the samples, 12 eyes had received an
intravitreal injection of Bevacizumab 1 week before surgery for PDR. In 11
additional diabetic patients, diabetic retinopathy was absent and vitrectomy
was performed for epimacular membrane or retinal detachment (Table 1). The
control group consisted of vitreous samples from 26 eyes of 26 nondiabetic
patients with an idiopathic macular hole, an idiopathic epiretinal membrane,
a rhegmatogenous retinal detachment, or age-related macular degeneration
(Table 1).
Microparticle isolation. Vitreous microparticles were isolated from fresh
vitreous drawn at beginning of the surgery. Vitreous was separated from cells
and platelets after two centrifugations (500g for 15 min and 13,500g for 5 min).
Venous blood samples (10 ml) were collected on citrated tubes before the eye
surgery and platelet-free plasma (PFP) from 60 patients and was immediately
prepared by successive centrifugations according to the methodology of
Amabile et al. (11). For each included patient, PFP and vitreous were frozen
and stored at 80°C until subsequent use. Samples were frozen and thawed
only once.
Materials. Monoclonal antibodies to vascular endothelial (VE)-Cadherin
(CD144) conjugated with phycoethrin, to human glycoprotein GPIIb (IIIa)
(CD41) conjugated with PC5, and their corresponding isotype IgG1 were from
Beckman Coulter, France. Human Annexin V solution conjugated with ﬂuo-
rescein isothiocyanate (FITC) was from Roche Diagnostics, France. Lectins
from arachis hypogaea peanut agglutinin (PNA) and from Bandeiraea Sim-
plicifolia Isolectin B4 (ILB4) conjugated with FITC were from Sigma Aldrich,
France. Human umbilical vein endothelial cells (HUVECs) (passage 3–6)
medium (Endothelium Cell Basal Medium) were obtained from Promocell
(Heidelberg, Germany). Cells were cultured in endothelial growth culture
medium at 37°C in a 95% air and 5% CO2 atmosphere. Matrigel basement
membrane matrix was purchased from BD Bioscience (San Jose, CA), and
female C57/BL6 mice (aged 7 weeks) purchased from Charles River Labs were
used for the Matrigel plug assay.
Microparticle labeling and ﬂow cytometry analysis. Analyses were per-
formed on a Coulter EPICS XL ﬂow cytometer (Beckman Coulter) by two
independent examiners unaware of the subject status. Human vitreous (60 l)
and PFP (20 l) were incubated with anti-CD41-PC5 (10 l), anti-CD144-PE
(20 l) antibodies, or their respective isotypic immunoglobulins. Micropar-
ticles expressing phosphatidylserine were labeled using FITC-conjugated
Annexin V solution in the presence of CaCl2 (5 mmol/l ﬁnal concentration)
according to the recommendation of the supplier. Microparticles from retinal
origins were labeled with lectins. FITC-conjugated lectins were diluted in PBS
to reach the ﬁnal concentration of 100 g/ml. Human vitreous (60 l) was
incubated with either lectin from PNA FITC (20 g) or lectin from ILB4 FITC
(4 g) (25,26). Their respective controls were preincubated with D-galactose
(80 mmol/l for 30 min) (Sigma-Aldrich) (27–29). Microparticles were gated as
events with a 0.1-to 1.0-m diameter identiﬁed in forward-scatter and side-
scatter intensity dot-plot representation using standards synthetic beads of 1
m in diameter (Polyscience) (Fig. 1). Microparticle concentration was
assessed by comparison with calibrator Flowcount beads (10 m diameter;
Beckman Coulter) with a predetermined concentration.
Isolation of vitreous microparticles for assessment of cell proliferation
and angiogenesis. To study properties of vitreous microparticles on HUVEC
proliferation and angiogenesis, microparticles were isolated from vitreous
samples pooled from six consecutive patients with PDR. Patients who
previously had intravitreal anti-VEGF therapy injection or complete panpho-
tocoagulation were excluded. Microparticles were pelleted and washed three
times in endothelial growth culture medium medium (20,500g for 150 min). At
the end of the last centrifugation, the supernatant was ﬁltered with 0.2 m
and then 0.1 m Acrodisc PF Syringe Filter (PALL Life Sciences) and used as
vehicle. Levels of endothelial CD144
 microparticles, the most abundant
vitreous microparticle subpopulation in patients with PDR, were determined
in each pellet using ﬂow cytometry, and all proliferation experiments were
performed at the ﬁnal concentration of 65 CD144
 microparticles/l. Vitreous
microparticles isolated using this procedure did not contain detectable levels
of VEGF when determined by immunoassay (minimal detection limit of 3.3
pg/ml; n  6).
Assessment of cell proliferation. Endothelial cell proliferation was evalu-
ated by
3H-thymidine (Amersham; Biosciences) incorporation in subconﬂuent
quiescent HUVECs. At 70% conﬂuence, endothelial cells were rendered
quiescent by replacing 10% FCS with 0.1% BSA for 24 h. Endothelial cells were
then incubated during 48 h with either 10% FCS (used as a positive control),
vitreous microparticles from patients with PDR (corresponding to a ﬁnal
concentration of 65 microparticles/l of microparticles of endothelial origin),
or vehicle. The concentration of microparticles used in these experiments was
TABLE 1
Baseline characteristics of the patients, ophthalmology features,
and performed therapies
Diabetic patients
Control
subjects
Patients (n)/eyes (n) 104/109 26/26
Sex (male) 63 (61) 11 (42)
Age (years) 52  26 8  2*
A1C (%) 6.9  2.8 —
Type 1/type 2 diabetes 72/32 —
Insulin treatment 73 (70) —
Eyes with PDR (n) 98 with/11 without —
Creatinin clearance (ml/min) 74.3  3.8 74.8  4.6
Hypertension 77 (74) 13 (50)
Dyslipidemia 53 (51%) 5 (18)
Smoking 32 (31) 6 (22)
Ophthalmology features
(n eyes)
PDR 98 (90) 0
PDR with vitreous
haemorrhage 63 0
PDR with tractional retinal
detachment 22 0
PDR or macular edema 14 0
Epimacular membrane 8 (7) 16 (62)
Macular hole 0 6 (23)
Rhegmatogenous retinal
detachment 3 (3) 2 (8)
Age-related macular
degenerescence 0 2 (8)
Therapies
Intravitreal injection of
Bevacizumab 12 (11) —
No panretinal laser
photocoagulation 13 (13.2) —
Incomplete panretinal laser
photocoagulation 58 (59.2) —
Complete panretinal laser
photocoagulation 27 (27.5) —
Data are n (%) unless otherwise indicated. *Signiﬁcant difference
between diabetic and control patients.
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from patients with PDR. After 48 h,
3H-thymidine was added (1 Ci/well) for
16 h at 37°C. Endothelial cell proliferation was stopped by freezing (80°C),
and free thymidine was then separated by ﬁltration on 1.2-m ﬁlters. The
counting of the radioactivity remaining on the ﬁlters (to determine thymidine
incorporated in endothelial cells) was then realized, after addition of a
Microscint solution (40 l/well), in a Microplate luminescence counter
(Perkin Elmer, Boston, MA).
Matrigel angiogenesis assay. All animal experiments were performed in
accordance with institutional animal care guidelines as previously described
(30). Brieﬂy, 500 l Matrigel (free of growth factors) mixed with vitreous
microparticles (reaching a level of 5,000 CD144
 microparticles of endothelial
origin) or vehicle was injected subcutaneously in the back of 16 7-week-old
C57/BL6 mice. After 7 days, mice were killed by intraperitoneal injection of 0.1
ml pentobarbital (Ceva Sante Animale, Libourne, France) and Matrigel plugs
were excised. Specimens were ﬁxed with 4% formaldehyde overnight at 4°C
and embedded in parafﬁn. Serial sections (5 m thick) were submitted to
Masson Trichrome staining. Two pathologists graded the samples in a masked
fashion and counted capillary structures (considering each area surrounded
by few contiguous cells forming a patent lumen as a capillary structure)
present on three different sections for every Matrigel plug (10, 20, and 40
magniﬁcation, Olympus BH-2; Leica).
Statistical analysis. Microparticles levels are expressed as median and
range and analyzed by Kruskall-Wallis nonparametric analysis to compare
levels between more than two groups, followed by Mann-Whitney analysis of
two groups when appropriate. Other data are expressed as means  SEM
according to the normality of distribution and analyzed by ANOVA followed
by appropriate Bonferonni tests or by Student’s t test. In addition, the 
2 test
was performed for frequency analysis of Matrigel angiogenesis assays. Statis-
tical analysis was performed with SPSS 10.0 software for Windows. Differ-
ences were considered signiﬁcant at P 	 0.05.
RESULTS
Characterization of circulating and vitreous micro-
particles. Microparticles were identiﬁed by ﬂow cytom-
etry analysis as events with 0.1–1 m positively labeled
by speciﬁc antibodies (Fig. 1). Speciﬁc microparticle
populations were deﬁned (Fig. 1): endothelium-derived
microparticles (EMPs) (CD144
 or VE-cadherin posi-
tive) and platelet-derived microparticles (PMPs) (CD41

or glycoprotein IIb positive) as previously described (11).
Photoreceptor-derived microparticles (PNA positive) and
microglial-derived microparticles (ILB4 positive) were
also identiﬁed.
Plasma levels of Annexin V
, platelet CD41
, and endo-
thelial CD144
 microparticles were not different in control
and diabetic patients (Table 2). Microparticles from retinal
origin (PNA
 or ILB4
 microparticles) were undetectable
in plasma samples (Table 2). Vitreous levels of Annexin
V
, platelet CD41
, and endothelial CD144
 micropar-
ticles were all markedly increased in diabetic compared
with control patients (P  0.035, 0.018, and 	0.001,
respectively) (Fig. 2). Microparticles of endothelial origin,
identiﬁed as expressing VE-cadherin (CD144), were the
most abundant microparticle subpopulation in vitreous
samples from diabetic patients. Vitreous levels of Annexin
V
, endothelial CD144
, and platelet CD41
 micropar-
ticles were increased in association with PDR compared
with nonPDR (NPDR) (P  0.007, 0.017, and 0.018, respec-
tively) (Table 2). In addition, vitreous levels of Annexin V
,
platelet CD41
, and endothelial CD144
 microparticles were
augmented in diabetic patients with PDR compared with
control subjects (P  0.004, 0.003, and 	0.0001, respectively
(Fig. 2). However, there were no differences between vitre-
ous levels of retinal microparticles (ILB4
 and PNA
)i n
diabetic patients and control patients. Furthermore, circulat-
ing levels of endothelial-and platelet-derived microparticles
were not different between control and diabetic patients with
or without PDR (Fig. 2).
The ratio of vitreous to plasma microparticles levels
indicates the importance of intraocular formation versus
potential plasma leakage of microparticles from microves-
sels in vitreous ﬂuid (Fig. 3). For all markers, the ratio was
increased in PDR compared with control. This ratio was
markedly greater than unity for only endothelial CD144

microparticles in PDR (P  0.02), indicating either an
intraocular shedding or an abnormal clearance of endo-
thelial microparticles.
Effect of therapies on vitreous microparticles levels
in PDR. In patients with PDR, complete panretinal photo-
coagulation (PRP) signiﬁcantly decreased vitreous endo-
thelial microparticle levels (P  0.037) to reach values not
FIG. 1. Representative traces of ﬂow cytometry analysis of Annexin V
,
platelet, endothelial photoreceptor, and microglial microparticles in
human vitreous samples. A–E: Size-selected events (0.1–1.0 m) are
plotted as a function of their ﬂuorescence for speciﬁc Annexin V–FITC
binding (FL1) (A), lectin PNA-FITC labeling (B), anti-human CD144-
phycoethrin (PE) labeling (C), anti-human CD41-PC5 labeling (D), or
lectin ILB4-FITC labeling (E). Gray-shaded areas represent unspeciﬁc
labeling determined either in the absence of calcium (A), ﬂuorescent
isotypic antibodies (C and D), or D-Galactose (B and E). F: Ultrastruc-
tural analyses of vitreous microparticles. Transmission electron micro-
scopic picture of vitreous section showing clustering vitreous vesicles
with negative staining. Following samples embedding in Epon 812, thin
sections were layed on a carbon-coated grid, stained with 7.6% uranyl
acetate and 0.4% lead citrate, and then examined by electron micros-
copy (Phillips, Eindhoven, the Netherlands; Tecnai, Fei, U.S.). Scale
bar: 0.1 m. FL1, green ﬂuorescence; FL2, orange ﬂuorescence; FL4,
infrared ﬂuorescence.
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plete laser treatment tended to decrease vitreous levels of
Annexin V
, CD41
,o rP N A
 microparticles but the
change did not reach statistical signiﬁcance (Fig. 4).
One week prior to vitrectomy, 12 patients with PDR
received an intravitreal injection of Bevacizumab (50 l;
25 g/l), a humanized recombinant antibody binding all
isoforms of VEGF-A, which causes at least short-term
involution of retinal neovascularization, therefore reduc-
ing the risk of hemorrhage during surgery (Fig. 4). Bevaci-
zumab treatment signiﬁcantly decreased vitreous levels of
Annexin V
 microparticles and endothelial CD144
 micro-
particles (P  0.04 and P  0.02, respectively) and led to
a complete disappearance of platelet-derived CD41
 mi-
croparticles in PDR vitreous samples (Fig. 4). However,
anti-VEGF treatment did not affect levels of photoreceptor
microparticles (PNA
). Following Bevacizumab treat-
ment, vitreous levels of endothelial CD144
 microparticles
were no longer different from those found in control
patients.
Vitreous microparticles induce endothelial cell pro-
liferation and new vessel formation. Vitreous micro-
particles or supernatant, as previously prepared, were
incubated with subconﬂuent quiescent HUVECs during
4 8h( n  4). Vitreous microparticles signiﬁcantly in-
creased
3H-thymidine incorporation, by 1.6-fold, compared
with microparticle vehicle (vitreous supernatant; P 
0.029). FCS (10%; used here as a positive control) in-
creased
3H-thymidine incorporation by 2.4-fold (P  0.003)
(Fig. 5A). Vitreous microparticles did not contain detect-
able levels of VEGF when determined by immunoassay
with a minimal detection limit of 3.3 pg/ml (n  6). In the
in vivo Matrigel plug assay, vitreous microparticles signif-
icantly induced endothelial cell migration (score 1) and
new vessels formation (score 2) compared with vehicle
(vitreous supernatant; score 0) (P  0.001) (Fig. 5B).
DISCUSSION
This study reveals, for the ﬁrst time, the presence of
submicron membrane vesicles shed from platelet, endo-
thelial, and retinal cells in human vitreous samples of
patients undergoing vitrectomy and demonstrates the spe-
ciﬁc vitreous accumulation of endothelial microparticles
in patients with PDR. In addition, we show that vitreous
microparticles isolated from patients with diabetic reti-
nopathy stimulate endothelial cell proliferation and forma-
tion of new vessels, suggesting that they could contribute
to retinal angiogenesis.
Presence of shed-membrane microparticles has been
reported in several human body ﬂuids, such as plasma or
synovial ﬂuid (13,15,16). Plasma levels of microparticles of
different cellular origins are increased in patients with high
atherothrombotic risk or inﬂammatory diseases (15,16,31).
In this study, we observed no signiﬁcant differences in
circulating microparticle levels between diabetic patients
and the control group. However, our diabetic group in-
cluded mostly patients with type 2 diabetes, a disease for
which conﬂicting results on changes in circulating micro-
particles have been reported (17–20). Another potential
confounding factor is that signiﬁcant numbers of patients
from the control group have cardiovascular risk factors
such as hypertension or dislipidemia, which are known to
TABLE 2
Plasma levels of microparticles in control patients and in patients with or without PDR
Plasma Vitreous
Control NPDR PDR Control NPDR PDR
N 26 6 28 26 6 28
Annexin V
 microparticles 1,223 (7–5,686) 1,436 (130–2,871) 721 (10–6,068) 18 (0–633) 9 (2–43) 92 (2–1,349)*†
CD41
 microparticles 765 (25–5,018) 718 (68–1,763) 408 (8–2,845) 15 (0–156) 12 (1–58) 64 (2–728)*†
CD144
 microparticles 98 (14–901) 190 (31–609) 89 (21–4,402) 44 (0–378) 52 (18–336) 149 (13–900)*†
PNA
 microparticles 0 0 0 6 (0–79) 19 (0–64) 17 (0–791)
ILB4
 microparticles 0 0 0 0 (0–117) — 33 (0–184)
Data are expressed as median (range) of microparticles/l. Microparticles were identiﬁed of platelet (CD41
) and endothelial (CD144
)
origin or from retinal origin (PNA
 and ILB4
). Annexin V
 microparticles express phosphatidyserine and were positively labeled with
Annexin V. Microparticles levels were analyzed by Kruskall-Wallis nonparametric analysis followed by Mann-Whitney analysis of two groups
when appropriate. *†Signiﬁcant difference between NPDR and PDR or between nondiabetic patients and patients with PDR, respectively.
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FIG. 2. Vitreous levels of Annexin V
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) and microglial (ILB4
)
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particles (32,33).
PDR is associated with ocular increases in oxidative
stress, protein glycation, growth factors, inﬂammatory
cytokines, and cell apoptosis—all of which stimulate the
shedding of membrane microparticles from retinal or
vascular cells (1,4,15,16,21,22,24,34,35). We observed sig-
niﬁcant increases in the overall pool of vitreous Annexin
V
 microparticles in PDR compared with control patients
or patients with nonproliferative diabetic retinopathy. In
addition, we demonstrate the presence of microparticles
positively labeled with either PNA or ILB4 in vitreous
samples but not in plasma, indicating their photoreceptor
or microglial origin, respectively (25–29). If anything,
levels of microparticles derived from photoreceptors or
microglia tend to increase in patients with PDR, but the
difference did not reach statistical signiﬁcance. These
microparticles originate from cells localized in deeper
retinal layers and may be released in vitreous ﬂuid follow-
ing the tear of the retinal internal limiting membrane.
Microfracture of the internal limiting membrane is a likely
hypothesis in our control patients, who were included for
epimacular membrane or macular hole, and even more so
in patients with PDR, where proliferating microvessels
need to perforate the internal limiting membrane (36,37).
The present study also demonstrates increased vitreous
levels of microparticles originating from vascular or circu-
lating cells such as platelets. Diabetic retinopathy is char-
acterized by an augmented vascular permeability, and
microparticles present in the blood could permeate
through the leaky vascular wall into the vitreous ﬂuid. By
the same token, vitreous microparticles expressing endo-
thelial VE-cadherin may originate from the circulating pool
of microparticles, but they may be also locally generated
from the retinal new vessel wall. To appreciate the relative
importance of local formation versus potential leakage of
microparticle from microvessels into the vitreous ﬂuid, we
determined the ratio of vitreous to plasma microparticles
levels. This ratio was greater than unity only for endothe-
lial CD144
 microparticles in diabetic patients with PDR,
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(PRP), complete PRP, or intravitreal injection of Bevacizumab prior to vitrectomy. *Signiﬁcantly different when comparing patients with PDR
with those with no or incomplete PRP.
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particles found in the vitreous ﬂuid could be generated
from local microvascular endothelial cells in PDR or that
clearance of endothelial microparticles was abnormal. On
the contrary, the ratio for platelet CD41
 microparticles
was lower than unity, favoring the interpretation that
platelet microparticles present in PDR vitreous ﬂuid likely
originate from the plasma.
We investigated the effects of two treatments of PDR on
vitreous levels of microparticles. Complete laser photoco-
agulation causes regression of preretinal neovasculariza-
tion by destroying the outer layers of the retina and
improving the oxygen diffusion from the choroid to the
inner retina (38–41), whereas intravitreal injection of the
anti-VEGF antibody Bevacizumab leads to a complete
resolution of angiographic leakage of neovasculariza-
tion and to a rapid involution of retinal neovasculariza-
tion (42–45). Both treatments decreased levels of
vitreous endothelial CD144
 microparticles to values no
longer different from those found in control patients.
These observations further reinforce our ﬁndings that
PDR is associated with a speciﬁc increase in local
shedding of endothelial microparticles originating from
new vessels. Furthermore, Bevacizumab decreased vit-
reous platelet CD41
 microparticles to undetectable
levels, which is a ﬁnding consistent with the decrease
vascular leakage reported for the anti-VEGF ocular
therapy (42,46).
The present study shows that vitreous microparticles
stimulate in vitro endothelial proliferation and in vivo
new-vessel formation in a Matrigel plug model. This ﬁnd-
ing is in agreement with previous studies showing that
microparticles of different cellular origins (platelet, leuko-
cyte, or endothelial) are proangiogenic (8–10,34,47). How-
ever, the present data contrast with studies reporting the
antiangiogenic effect of microparticles of endothelial or
lymphocyte origin, which is associated with the stimula-
tion of oxidative stress (48,49). The reasons for this
discrepancy are unknown but could result from the
different nature or composition of microparticles. Be-
cause of the paucity of microparticles in vitreous sam-
ples and their low recovery after isolation, we were
unable to identify the cell origin of vitreous micropar-
ticles that affect endothelial cells. Although the proan-
giogenic effect of platelet-derived microparticles is
mediated in part by growth factors (8), the mechanism
of the proliferative effect of vitreous microparticles
unlikely involves VEGF because levels of this growth
factor were below detection in isolated vitreous micro-
particles samples. Because of the low recovery of the
isolation procedure, the present data do not permit the
examination of the proangiogenic effect of vitreous
microparticles from nonproliferative diabetic retinopa-
thy or from control patients. For similar reasons, we
could not evaluate the biological effects of increasing
concentrations of vitreous microparticles.
In conclusion, we identiﬁed the presence in vitreous
ﬂuid of membrane microparticles shed from retinal, vas-
cular, and circulating cells and their signiﬁcant increase in
patients with PDR, where they could contribute to disease
progression.
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